If additional glycaemic control is needed after at least 30 days on 7 mg, the dose may be increased to 14 mg
Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine 104-week trial in 3,297 high-risk T2DM patients showed semaglutide reduced composite MACE by 26% versus placebo establishing cardiovascular benefit for GLP-1 receptor agonists
You will need to speak to a licensed health care provider
Typically, these effects are temporary and diminish as your body adapts
We ensure that you receive only the highest quality semaglutide and tirzepatide, thanks to our partnership with BuildMyHealth
However, GLP-1 medications significantly reduce appetite , which may make it harder for breastfeeding parents to consume enough calories, fluids, and nutrients needed for milk production